Products Categories
CAS No.: | 68401-81-0 |
---|---|
Name: | Ceftizoxime |
Article Data: | 7 |
Molecular Structure: | |
Formula: | C13H13N5O5S2 |
Molecular Weight: | 383.409 |
Synonyms: | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6a,7b(Z)]]-;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-(9CI);Ceftisomin;Ceftizoxime;Epocelin; |
Density: | 1.89 g/cm3 |
Melting Point: | 227° (dec) |
Solubility: | soluble in water, slightly soluble in methanol, a few not soluble in alcohol, acetone, chloroform, ether or ethyl acetate |
Appearance: | white or light ashy-yellow crystalline powder |
Hazard Symbols: | Xi |
PSA: | 200.75000 |
LogP: | 0.35420 |
(6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceftizoxime
Conditions | Yield |
---|---|
Stage #1: (6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid With dmap In dichloromethane at -8 - 0℃; Stage #2: C13H10N4O2S3 With dmap In dichloromethane at -5 - 0℃; for 0.25h; Reagent/catalyst; Temperature; | 97% |
pivaloyloxymethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-4-carboxylate
A
ceftizoxime
B
(2R,6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2-carboxylic acid
Conditions | Yield |
---|---|
With water In N,N-dimethyl-formamide at 37℃; Rate constant; phosphate buffer, var. pH; |
(6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(Z)-S-benzo[d]thiazol-2-yl 2-(2-aminothiazol-4-yl)-2-(methoxyimino)ethanethioate
ceftizoxime
Conditions | Yield |
---|---|
Stage #1: (6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid With triethylamine In chloroform for 0.333333h; Stage #2: (Z)-S-benzo[d]thiazol-2-yl 2-(2-aminothiazol-4-yl)-2-(methoxyimino)ethanethioate In chloroform at 35℃; for 4.5h; Temperature; | 87 g |
iodomethyl pivaloate
ceftizoxime
pivaloyloxymethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-4-carboxylate
Conditions | Yield |
---|---|
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification; | 73% |
ceftizoxime
(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetoxy-ethyl ester
Conditions | Yield |
---|---|
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification; |
ceftizoxime
(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-isopropoxycarbonyloxy-ethyl ester
Conditions | Yield |
---|---|
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification; |
ceftizoxime
(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester
Conditions | Yield |
---|---|
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification; |
ceftizoxime
Conditions | Yield |
---|---|
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification; |
ceftizoxime
(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
Conditions | Yield |
---|---|
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification; |
ceftizoxime
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C 2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C View Scheme |
The Ceftizoxime acid with CAS registry number of 68401-81-0 is also known as Ceftizoximum. The IUPAC name is (6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. Its classification codes are Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics; Drug/Therapeutic Agent. In addition, the formula is C13H13N5O5S2 and the molecular weight is 383.40. This chemical is a white or light ashy-yellow crystalline powder and soluble in water, slightly soluble in methanol.
Physical properties about Ceftizoxime acid are: (1)#H bond acceptors: 10; (2)#H bond donors: 4; (3)#Freely Rotating Bonds: 5; (4)Polar Surface Area:: 199.35Å2; (5)Rotatable Bond Count: 5; (6)Tautomer Count: 14; (7)Exact Mass: 383.03581; (8)MonoIsotopic Mass: 383.03581; (9)Topological Polar Surface Area: 201; (10)Heavy Atom Count: 25; (11)Complexity: 669; (12)Defined Atom StereoCenter Count: 2; (13)Defined Bond StereoCenter Count: 1; (14)Covalently-Bonded Unit Count: 1.
Preparation of Ceftizoxime acid. Firstly, chloride compounds (Ⅵ) is prepared by reaction of 2-methoxy-imino 2-(2-amino-1,3-thiazol-4-yl) acetic acid (V), phosphorus oxychloride, bis (trimethylsilyl) acetamide and dimethylformamide. Secondly, add trimethylsilyl acetamide to 7-ACA, then add the reaction mixture to chloride compounds (Ⅵ) . The reaction mixture is stirred at -10~-15 °C for 1 hour. At last, the reaction mixture is conducted with column chromatography and evaporated to obtained the product.
Uses of Ceftizoxime acid: it is used as third-generation cephalosporins, and also used for respiratory infections caused by susceptible strains, urinary tract infections, biliary tract infections, bone and joint infections, skin and soft tissue infections, gynecological diseases, sepsis, peritonitis, meningitis and endocarditis. What's more, it is primarily used for the treatment of respiratory system, urinary system, such as bone and joint infections.
You can still convert the following datas into molecular structure:
1. SMILES: CON=C(c1csc(=[NH2+])[nH]1)C(=O)NC2C3N(C2=O)C(=CCS3)C(=O)[O-]
2. InChI: InChI=1/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-
3. InChIKey: NNULBSISHYWZJU-IDUWFGFVBF
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
rat | LD50 | intravenous | 8gm/kg (8000mg/kg) | United States Patent Document. Vol. #4563522, | |
rat | LD50 | subcutaneous | > 8gm/kg (8000mg/kg) | United States Patent Document. Vol. #4563522, |